Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial: Veterans Affairs cooperative study on glycemic control and complications in type II diabetes

Archives of Internal Medicine

Volumn 157, Issue 2, 1997, Pages 181-188

  Abraira, Carlos ^b   Colwell, John ^e   Nuttall, Frank ^e   Sawin, Clark T ^e   Henderson, William ^e   Comstock, John P ^a   Emanuele, Nicholas V ^e   Levin, Seymour R ^b   Pacold, Ivan ^c,d   Lee, Hae Sook ^e  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d MACNEAL HOSPITAL   (United States)

^e Veterans Affairs Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CORRELATION FUNCTION; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SOLDIER;

EID: 0031018291     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.2.181     Document Type: Article

References (52)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. National Diabetes Data Group. Diabetes in America. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1985:ii-2.
3. Klein R, Klein BEK, Moss SE, Shrago ES, Spennetta TL. Gtycosylated hemoglobin in a population-based study of diabetes. Am J Epidemiol. 1987;126:415-428.
4. Abraira C, Maki K. Does insulin treatment increase cardiovascular risk in NIDDM? Clin Diabetes. 1995;13:29-31.
5. Laws A, Reaven GM. Insulin resistance and risk factors for coronary heart disease. Baillieres Clin Endocrinol Metab. 1993;7:1063-1078.
6. Donohue RP, Orchard TJ. Diabetes mellitus and vascular complications: an epidemiological perspective. Diabetes Care. 1992;15:1141-1155.
7. Henry RR, Wallace P, Gumbiner B, Lyon R, Ditzler T, Glauber HS. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care. 1993;16:21-31.
8. Randeree HA, Omar MAK, Motar AA, Seedat M. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care. 1992;15:1258-1263.
9. Santen RJ, Willis PW, Fajans SS. Atherosclerosis in diabetes meilitus. Arch Intern Med. 1972;130:833-843.
10. Manson JA, Colditz GA, Stampfer MJ, et al. A prospective study of maturity onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch intern Med. 1991;151:1141-1147.
11. Janka HU, Ziegler AG, Standl E, Mehnert H. Daily insulin dose as a predictor of macrovascular disease in insulin-treated non-insulin-dependent diabetics. Diabetes Metab Rev. 1987;13:359-364.
12. Taskinen MR, Kuusi T, Helve E, Nikkila E, Yki-Jarvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in non-insulindependent diabetes. Arteriosclerosis. 1988;8:168-177.
13. Clark RS, English M, McNeil GP, Newton RW. Effect of infusion of insulin in diabetics with acute myocardial infarction. BMJ. 1985;291:303-305.
14. University Group Diabetes Program, I: design, methods and baseline results. Diabetes. 1970;19(suppl 2):747-783.
15. University Group Diabetes Program, II: mortality results. Diabetes. 1970;19 (suppl 2):789-830.
16. University Group Diabetes Program, VII: evaluation of insulin therapy: final report. Diabetes. 1982;31:14.
17. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G. Hyperinsulinemia is not a major coronary risk factor in elderly men. Diabetologia. 1992;35:766-770.
18. Fu CC, Chang CJ, Tseng CH, et al. Development of macrovascular diseases in NIDDM patients in northern Taiwan: a 4-year follow-up study. Diabetes Care. 1993;16:137-143.
19. Rytter L, Troelsen S, Nielsen HB. Prevalence and mortality of acute myocardial infarction in patients with diabetes mellitus. Diabetes Care. 1985;8:230-234.
20. Ulvenstam G, Aberg A, Bergstand R, et al. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes. 1985;34:787-792.
21. Reiber G, Pecoraro RE, Koepsetl I. Risk factors for amputation in patients with diabetes mellitus. Ann Intern Med. 1992;117:97-105.
22. Moss SE, Klein R, Klein BEK, Meuer S. The association of glycemia and causespecific mortality in a diabetic population. Arch Intern Med. 1994;154:2473-2479.
23. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia. 1993;36:1175-1184.
24. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes. 1994;43:960-967.
25. Elliott TG, Viberti G. Relationship between insulin resistance and coronary heart disease in diabetes mellitus and the general population: a critical appraisal. Baillieres Clin Endocrinol Metab. 1993;7:1079-1102.
26. Abraira C, Emanuele N, Colwell J, et al. Glycemic control and complications in type II diabetes: design of a feasibility trial. Diabetes Care. 1992;15:1560-1571.
27. Abraira C, Colwell JA, Nuttall FQ, et al. VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes: results of the feasibility trial. Diabetes Care. 1995;18:1113-1123.
28. Detection and treatment of complications of type II diabetes mellitus. In: Rifkin M, ed. Physician's Guide to Type II Diabetes. 2nd ed. Alexandria, Va: American Diabetes Association: 1988:68-69.
29. Stamler J, Prineas RJ, Neaton JD, et al. Background and design of the new US Trial on Diet and Drug Treatment of 'Mild' Hypertension (TOMHS). Am J Cardiol. 1987;59:50G-51G.
30. Prineas RJ, Crow RS, Blackburn H. The Minnesota Code Manual of Electrocardiographic Findings: Standards and Procedures for Measurement Classification. Littleton, Mass: John Wright-PSG Inc; 1982.
31. Rautaharju PM, LaCroix AZ, Savage DD, et al. Electrocardiographic estimates of left ventricular mass versus radiographic cardiac size and the risk of cardiovascular disease mortality in the epidemiologic follow-up study of the first National Health and Nutrition Examination Survey. Am J Cardiol. 1988;62:59-66.
32. Bikkina M, Larson MG, Levy D. Prognostic implication of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med. 1992;117:990-996.
33. Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial. N Engl J Med. 1984;311:365-372.
34. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin-dependent diabetes mellitus: the Oslo Study. BMJ. 1985;290:811-815.
35. Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237-1245.
36. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
37. Duh E, Feinglos M. Hypoglycemia-induced angina pectoris in a patient with diabetes mellitus. Ann Intern Med. 1994;121:945-946.
38. Davidson JK, Zwagg RV, Cox CL, et al. The Memphis and Atlanta continuing care programs for diabetes, II: comparative analyses of demographic characteristics, treatment methods, and outcomes over a 9-10-year follow-up period. Diabetes Care. 1984;7:25-31.
39. National Diabetes Advisory Board. Progress and Promise in Diabetes Research. Washington, DC: US Dept of Public Health; 1984:37.
40. Hanefeld M, Fischer S, Schemeckel M, et al. Diabetes Intervention Study: multiintervention trial in newly diagnosed NIDDM. Diabetes Care. 1991;14:308-317.
41. Gallagher AM, Abraira C, Henderson WG. A four-year prospective trial of unmeasured diet in lean diabetic adults. Diabetes Care. 1984;7:557-565.
42. Klein R, Klein BEK, Moss SE. Visual impairment in diabetes. Ophthalmology. 1984;91:1-9.
43. Ferris FL. How effective are treatments for diabetic retinopathy? JAMA. 1993;269:1290-1291.
44. DeFronzo R. Nephropathy. In: Lebovitz HE, ed. Therapy for Diabetes Mellitus and Related Disorders. Alexandria, Va: American Diabetes Association; 1991:248-260.
45. Noth RM. Diabetic nephropathy: hemodynamic basis and implications for disease management. Ann Intern Med. 1989;110:795-813.
46. Bakris G. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy. Ann Intern Med. 1993;118:643-644.
47. Siperstein MD, Browner WS. The case for moderate rather than tight glucose control in insulin-dependent diabetes mellitus. Clin Diabetes. 1995;13:7-9.
48. Krolewski AS, Laffel LMB, Korlewski BA, Quinn M, Warran JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995;332:1251-1255.
49. Warram JH, Masson JE, Krolewski AS. Glycosylated hemoglobin and the risk of retinopathy in insulin-dependent diabetes mellitus. N Engl J Med. 1995;332:1305-1306.
50. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA. 1988;260:2864-2871.
51. Dahl-Jorgensen K, Brinchmann-Hansen O, Baugstad HJ, Haussen KF. Blood glucose control and microvascular complications: what do we do now? Diabetologia. 1994;37:1172-1177.
52. Viberti G. A glycemic threshold for diabetic complications? N Engl J Med. 1995;332:1293-1294.